文献速递肝病

直接抗病毒药物治疗丙型肝炎对死亡率的影响:基于大型人群队列研究

Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
PubMed 文献 · J Hepatol · 2021-06-25

该研究基于加拿大不列颠哥伦比亚省丙型肝炎检测者队列,评估直接抗病毒药物(DAA)诱导的持续病毒学应答(SVR)对全因、肝病相关及药物相关死亡率的影响。研究纳入10,851例DAA治疗者(SVR率96%)和10,851例匹配未治疗者,中位随访2.2年。结果显示SVR与全因死亡率(aHR 0.19)、肝病死亡率(asHR 0.22)和药物相关死亡率(asHR 0.26)显著降低相关。

要点

  • DAA诱导的SVR与全因死亡率显著降低相关(aHR 0.19)。
  • SVR与肝病相关死亡率(asHR 0.22)和药物相关死亡率(asHR 0.26)降低相关。
  • 注射吸毒及相关 syndemic 因素与药物相关死亡风险升高相关。

核心结论

  • DAA治疗与全因、肝病相关及药物相关死亡率的大幅降低相关。

研究设计与样本

  • 基于人群的队列研究,使用不列颠哥伦比亚省丙型肝炎检测者队列数据,纳入10,851例DAA治疗者和10,851例匹配未治疗者,采用逆概率治疗加权和多变量比例风险模型。

主要发现

  • SVR组全因死亡率为19.5/1000人年(死亡552例),无SVR组为86.5/1000人年(死亡96例),未治疗组为99.2/1000人年(死亡2,133例)。
  • 中位随访时间2.2年(IQR 1.3-3.6;最长6.2年)。
  • 多变量模型中,SVR与全因死亡率降低相关(aHR 0.19;95% CI 0.17-0.21)。
  • SVR与肝病相关死亡率降低相关(asHR 0.22;95% CI 0.18-0.27)。
  • SVR与药物相关死亡率降低相关(asHR 0.26;95% CI 0.21-0.32)。

临床怎么用

  • DAA治疗应作为丙型肝炎患者降低死亡风险的重要策略。
  • 对注射吸毒者需整合社会支持、成瘾治疗和HCV护理的综合方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We evaluated the effect of direct-acting antiviral (DAA)-induced sustained virologic response (SVR) on all-cause, liver- and drug-related mortality in a population-based cohort in British Columbia, Canada. METHODS: We used data from the British Columbia Hepatitis Testers Cohort, which includes people tested for HCV since 1990, linked with data on medical visits, hospitalizations, prescription drugs and mortality. We followed people who received DAAs and people who did not receive any HCV treatment to death or December 31, 2019. We used inverse probability of treatment weighting to balance the baseline profile of treated and untreated individuals and performed multivariable proportional hazard modelling to assess the effect of DAAs on mortality. RESULTS: Our cohort comprised 10,851 people treated with DAAs (SVR 10,426 [96%], no-SVR: 425) and 10,851 matched untreated individuals. Median follow-up time was 2.2 years (IQR 1.3-3.6; maximum 6.2). The all-cause mortality rate was 19.5/1,000 person-years (PY) among the SVR group (deaths = 552), 86.5/1,000 PY among the no-SVR group (deaths = 96), and 99.2/1,000 PY among the untreated group (deaths = 2,133). In the multivariable model, SVR was associated with significant reduction in all-cause (adjusted hazard ratio [aHR] 0.19; 95% CI 0.17-0.21), liver- (adjusted subdistribution HR [asHR] 0.22, 95% CI 0.18-0.27) and drug-related mortality (asHR 0.26, 95% CI 0.21-0.32) compared to no-treatment. Older age and cirrhosis were associated with higher risk of liver-related mortality while younger age, injection drug use (IDU), problematic alcohol use and HIV/HBV co-infections were associated with a higher risk of drug-related mortality. CONCLUSIONS: DAA treatment is associated with a substantial reduction in all-cause, liver- and drug-related mortality. The association of IDU and related syndemic factors with a higher risk of drug-related mortality calls for an integrated social support, addiction, and HCV care approach among people who inject drugs. LAY SUMMARY: We assessed the effect of treatment of hepatitis C virus infection with direct-acting antiviral drugs on deaths from all causes, liver disease and drug use. We found that treatment with direct-acting antiviral drugs is associated with substantial lowering in risk of death from all causes, liver disease and drug use among people with hepatitis C virus infection.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Janjua NZ, Wong S, Abdia Y, et al. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. J Hepatol. 2021. PMID: 34097994. doi:10.1016/j.jhep.2021.05.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。